Shared on25 Sep 25Fair value Increased 10%
Analysts have raised their price target for HLS Therapeutics to CA$7.41, citing positive impacts from share buybacks, debt reduction, and an expanding product portfolio, alongside signs of adjusted EBITDA recovery and improved operational performance. Analyst Commentary Share buybacks and debt reduction are viewed positively for capital allocation and balance sheet strength.
Shared on17 Apr 25Fair value Increased 2.91%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 8.55%
AnalystConsensusTarget has decreased profit margin from 2.7% to 0.7%, increased future PE multiple from 97.6x to 358.0x and increased shares outstanding growth rate from -0.0% to -0.0%.